Mobile

A Phase 2 Study of Ruxolitinib in Combination With Pemetrexed/Cisplatin and for Treatment of Subjects With Advanced Lung Cancer Estudio Fase IIde Ruxolitinib en combinación con Pemetrexed/Cispla...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-001436-10

A Phase 2 Study of Ruxolitinib in Combination With Pemetrexed/Cisplatin and for Treatment of Subjects With Advanced Lung Cancer Estudio Fase IIde Ruxolitinib en combinación con Pemetrexed/Cisplatino y Pemetrexed para el tratamiento de pacientes con cáncer de pulmón avanzado

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

?Part 1: To evaluate the safety and tolerability of ruxolitinib in combination with pemetrexed/cisplatin and select a dose for further evaluation ?Part 2: To evaluate and compare the OS of subjects with nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent when treated with ruxolitinib or placebo in combination with pemetrexed/cisplatin and subsequently pemetrexed maintenance

Critère d'inclusion

  • Nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent,CPCNP no escamoso en estadio IIIB, estadio IV o recurrente

Liens